var data={"title":"Anthelminthic therapies","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Anthelminthic therapies</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/contributors\" class=\"contributor contributor_credentials\">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Helminths are multicellular parasites with complex life cycles within and outside of human hosts. The mechanisms of action for many anthelminthic agents remain incompletely understood.</p><p>Anthelminthic drugs are used for treatment of symptomatic disease and for mass drug treatment programs in regions with high prevalence of infection and disease [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In some endemic areas, deworming strategies have been associated with health benefits including improvements in hemoglobin levels, growth and physical fitness, cognitive performance, and nutritional status [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/3,4\" class=\"abstract_t\">3,4</a>]. (See <a href=\"topic.htm?path=mass-drug-administration-for-control-of-parasitic-infections\" class=\"medical medical_review\">&quot;Mass drug administration for control of parasitic infections&quot;</a>.)</p><p>In the United States, some agents are available through the <a href=\"http://www.cdc.gov/ncezid/dsr/&amp;token=mjmpv7xMHRIW2nr+3NCnscGr7YZj3+TaUQHjLeVc6/9tVrAq2I7ZOx652HxKa09u&amp;TOPIC_ID=487\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention Drug Service</a> (telephone 1-404-639-3670).</p><p>An overview of anthelminthic therapies will be presented here. Therapeutic and more detailed considerations for specific helminth infections are discussed separately. (See related topics.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">IVERMECTIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is a semisynthetic derivative of avermectin, which is derived from the soil mold <em>Streptomyces avermitilis</em>. Ivermectin opens glutamate-sensitive chloride channel currents in helminths, and this may be its mechanism of action [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/5\" class=\"abstract_t\">5</a>].</p><p><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. (See <a href=\"topic.htm?path=onchocerciasis\" class=\"medical medical_review\">&quot;Onchocerciasis&quot;</a> and <a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">&quot;Strongyloidiasis&quot;</a>.)</p><p><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> has activity against other filarial worms including <em>Wuchereria bancrofti</em>, <em>Brugia malayi</em>, <em>Mansonella ozzardi</em>, and <em>Loa loa</em>. It is not the drug of choice for these infections, though it may be useful in certain circumstances. (See related topics.)</p><p><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is effective against several intestinal nematodes including ascariasis, trichuriasis, and enterobiasis [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/6\" class=\"abstract_t\">6</a>]. Ivermectin is also used to treat cutaneous larva migrans. Ivermectin is ineffective against human hookworms [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=ascariasis\" class=\"medical medical_review\">&quot;Ascariasis&quot;</a> and <a href=\"topic.htm?path=enterobiasis-pinworm-and-trichuriasis-whipworm\" class=\"medical medical_review\">&quot;Enterobiasis (pinworm) and trichuriasis (whipworm)&quot;</a> and <a href=\"topic.htm?path=hookworm-related-cutaneous-larva-migrans\" class=\"medical medical_review\">&quot;Hookworm-related cutaneous larva migrans&quot;</a>.)</p><p><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is also effective for treatment of ectoparasitic infections including scabies and head lice. (See <a href=\"topic.htm?path=scabies-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Scabies: Epidemiology, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=pediculosis-capitis\" class=\"medical medical_review\">&quot;Pediculosis capitis&quot;</a>.)</p><p><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> should not be administered to pregnant or lactating women, and its safety in children &lt;15 kg is not known. In areas of West Africa where loiasis is endemic, ivermectin should be used with caution; it should be avoided in those with high-grade microfilaremia who are susceptible to treatment-induced encephalopathy. (See <a href=\"topic.htm?path=loiasis-loa-loa-infection\" class=\"medical medical_review\">&quot;Loiasis (Loa loa infection)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">BENZIMIDAZOLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The benzimidazole class of antiparasitic agents includes four drugs: thiabendazole, <a href=\"topic.htm?path=mebendazole-drug-information\" class=\"drug drug_general\">mebendazole</a>, <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a>, and triclabendazole.</p><p>Benzimidazoles exert their anthelminthic effect by binding to free beta-tubulin and thus inhibiting the polymerization of tubulin and microtubule-dependent glucose uptake [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Benzimidazoles should be avoided in pregnant women when possible. When used in mass drug treatment programs for soil-transmitted helminths, the World Health Organization indicates that <a href=\"topic.htm?path=mebendazole-drug-information\" class=\"drug drug_general\">mebendazole</a> and <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> may be administered to pregnant women in the second and third trimesters [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Albendazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. (See related topics.)</p><p><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> also has activity against a number of less common tissue nematode infections, including cutaneous larva migrans [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/8\" class=\"abstract_t\">8</a>], visceral and ocular larva migrans [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/9\" class=\"abstract_t\">9</a>], gnathostomiasis [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/10\" class=\"abstract_t\">10</a>], intestinal capillariasis [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/11\" class=\"abstract_t\">11</a>], clonorchiasis [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/12\" class=\"abstract_t\">12</a>], <em>Lagochilascaris minor</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/13\" class=\"abstract_t\">13</a>], and human infections with the nematodes <em>Trichinella pseudospiralis</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/14\" class=\"abstract_t\">14</a>] and <em>Oesophagostomum bifurcum</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/15\" class=\"abstract_t\">15</a>]. (See related topics.)</p><p>Absorption of <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> is enhanced by taking it with fatty meals [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/16\" class=\"abstract_t\">16</a>]. Albendazole should be taken with fatty foods for treatment of invasive systemic parasitic infections; it should be taken with no food (eg, on an empty stomach) for treatment of intraluminal parasitic infections with no systemic involvement. Side effects of albendazole include abdominal pain, nausea, vomiting, and increased hepatic transaminases; these are generally transient and usually do not require discontinuation of the drug [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/17\" class=\"abstract_t\">17</a>]. Neutropenia and, rarely, agranulocytosis can occur with longer-term treatments (as for echinococcosis or neurocysticercosis), so blood counts should be monitored. Alopecia can occur during prolonged treatments but resolves after albendazole treatment ends.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Mebendazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mebendazole-drug-information\" class=\"drug drug_general\">Mebendazole</a> is a benzimidazole derivative that is effective against a spectrum of intestinal and tissue nematode infections, including ascariasis, hookworm, enterobiasis, and trichuriasis, and as an investigational drug for <em>Capillaria</em>. Side effects of mebendazole include mild abdominal pain and diarrhea. Mebendazole is not available in the United States.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Triclabendazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Triclabendazole is the drug of choice for treatment of liver fluke infections due to <em>Fasciola hepatica</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Triclabendazole should be taken with food to enhance absorption [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/20\" class=\"abstract_t\">20</a>]. (See <a href=\"topic.htm?path=liver-flukes-fascioliasis\" class=\"medical medical_review\">&quot;Liver flukes: Fascioliasis&quot;</a>.)</p><p>In the United States, triclabendazole is available through the Centers for Disease Control and Prevention under an investigational protocol (telephone 1-404-718-4745 or email parasites@cdc.gov). It may also be obtained from Victoria Pharmacy in Zurich, Switzerland.</p><p class=\"headingAnchor\" id=\"H21576281\"><span class=\"h2\">Thiabendazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thiabendazole is an older benzimidazole derivative that is active against a variety of nematode parasites, but frequent and severe side effects have limited its use [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/21\" class=\"abstract_t\">21</a>]. Adverse reactions include dizziness, nausea, vomiting, drowsiness, pruritus, headache, neuropsychiatric disturbances, hepatitis, and hypersensitivity reactions including Stevens-Johnson syndrome. A topical suspension of thiabendazole has been used for cutaneous larva migrans.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">PRAZIQUANTEL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of <em>Fasciola hepatica</em>). (See related topics.)</p><p>Its mechanism of action is unknown, but, in schistosomes, it causes paralysis and tegumental disruption. Side effects include headache, dizziness, drowsiness, nausea, and abdominal discomfort.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">OTHER AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of other drugs are available for the treatment of specific helminthic infections.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Diethylcarbamazine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Diethylcarbamazine</a> (DEC) is a piperazine derivative that has activity against lymphatic filariasis, loiasis, and visceral larva migrans. The mechanism of action is uncertain.</p><p>Side effects in filarial infections are generally proportional to the microfilarial burden and largely attributable to release of lipopolysaccharides and other constituents from endosymbiont <em>Wolbachia</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Symptoms include fever, headache, dizziness, and transient exacerbation of lymphangitis. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg, pruritus, ocular and constitutional symptoms). In areas of West Africa where loiasis is endemic, DEC should be used with caution; it should not be administered to individuals with high-grade microfilaremia who are susceptible to treatment-induced encephalopathy. (See <a href=\"topic.htm?path=loiasis-loa-loa-infection\" class=\"medical medical_review\">&quot;Loiasis (Loa loa infection)&quot;</a>.)</p><p>In the United States, DEC is available from the <a href=\"http://www.cdc.gov/ncezid/dsr/&amp;token=mjmpv7xMHRIW2nr+3NCnscGr7YZj3+TaUQHjLeVc6/9tVrAq2I7ZOx652HxKa09u&amp;TOPIC_ID=487\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention Drug Service</a>.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Pyrantel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyrantel is a well-tolerated pyrimidine derivative that acts against intestinal nematodes by inducing neuromuscular paralysis, allowing worms to be expelled. A single dose is usually curative for ascariasis, enterobiasis, and trichostrongyliasis; several doses are recommended for hookworm infection. (See <a href=\"topic.htm?path=ascariasis\" class=\"medical medical_review\">&quot;Ascariasis&quot;</a> and <a href=\"topic.htm?path=enterobiasis-pinworm-and-trichuriasis-whipworm\" class=\"medical medical_review\">&quot;Enterobiasis (pinworm) and trichuriasis (whipworm)&quot;</a> and <a href=\"topic.htm?path=miscellaneous-nematodes\" class=\"medical medical_review\">&quot;Miscellaneous nematodes&quot;</a> and <a href=\"topic.htm?path=hookworm-infection\" class=\"medical medical_review\">&quot;Hookworm infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Nitazoxanide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">Nitazoxanide</a> is a nitrothiazolyl-salicylamide derivative with an uncertain mechanism of action [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/24\" class=\"abstract_t\">24</a>]. Nitazoxanide has US Food and Drug Administration approval for treatment of two protozoan enteric infections, giardiasis and cryptosporidiosis. (See <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-cryptosporidiosis\" class=\"medical medical_review\">&quot;Treatment and prevention of cryptosporidiosis&quot;</a>.)</p><p>There is limited clinical experience with <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">nitazoxanide</a> for treatment of intestinal helminths including <em>Ascaris</em>, <em>Trichuris</em>, <em>Enterobius</em>, as well as the dwarf tapeworm, <em>Hymenolepis nana</em>, and <em>Fasciola hepatica</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/1,25\" class=\"abstract_t\">1,25</a>].</p><p class=\"headingAnchor\" id=\"H21576467\"><span class=\"h2\">Oxamniquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oxamniquine is a tetrahydroquinolone derivative that is used as an alternative agent for the treatment of <em>Schistosoma mansoni</em> [<a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/1\" class=\"abstract_t\">1</a>]. Higher doses are required in Egypt and South Africa for partially resistant strains; completely resistant strains have also been encountered. Oxamniquine is well tolerated, with occasional side effects of headache, dizziness, drowsiness, and gastrointestinal disturbances. Oxamniquine is contraindicated for use during pregnancy and is not available in the United States. (See <a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis\" class=\"medical medical_review\">&quot;Treatment and prevention of schistosomiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21576510\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Helminths are multicellular parasites with complex life cycles within and outside of human hosts. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. Ivermectin is effective against several intestinal nematodes including ascariasis, trichuriasis, and enterobiasis. Ivermectin is also effective for treatment of ectoparasitic infections including scabies and head lice. (See <a href=\"#H2\" class=\"local\">'Ivermectin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> has activity against other filarial worms including <em>Wuchereria bancrofti</em>, <em>Brugia malayi</em>, <em>Mansonella ozzardi</em>, and <em>Loa loa</em>; it is not the drug of choice for these infections, though it may be useful in certain circumstances. (See <a href=\"#H2\" class=\"local\">'Ivermectin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. Albendazole also has activity against a number of less common tissue nematode infections. (See <a href=\"#H9\" class=\"local\">'Albendazole'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Triclabendazole is the drug of choice for treatment of liver fluke infections due to <em>Fasciola hepatica</em>. (See <a href=\"#H16\" class=\"local\">'Triclabendazole'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of <em>Fasciola hepatica</em>). (See <a href=\"#H17\" class=\"local\">'Praziquantel'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=diethylcarbamazine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Diethylcarbamazine</a> (DEC) has activity against lymphatic filariasis, loiasis, and visceral larva migrans. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg, pruritus, ocular and constitutional symptoms). (See <a href=\"#H19\" class=\"local\">'Diethylcarbamazine'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Drugs for Parasitic Infections, 3rd Ed, The Medical Letter, New Rochelle, NY 2013.</li><li class=\"breakAll\">World Health Organizaton. Preventive chemotherapy in human helminthiasis: Coordinated use of anthelminthic drugs in control interventions: A manual for health professionals and programme managers. WHO, Geneva 2006. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103_eng.pdf (Accessed on May 31, 2017).</li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/3\" class=\"nounderline abstract_t\">Ojha SC, Jaide C, Jinawath N, et al. Geohelminths: public health significance. J Infect Dev Ctries 2014; 8:5.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/4\" class=\"nounderline abstract_t\">Taylor-Robinson DC, Maayan N, Soares-Weiser K, et al. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance. Cochrane Database Syst Rev 2012; 11:CD000371.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/5\" class=\"nounderline abstract_t\">Fox LM. Ivermectin: uses and impact 20 years on. Curr Opin Infect Dis 2006; 19:588.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/6\" class=\"nounderline abstract_t\">Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40:304.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/7\" class=\"nounderline abstract_t\">Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/8\" class=\"nounderline abstract_t\">Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol 1993; 129:588.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/9\" class=\"nounderline abstract_t\">Bhatia V, Sarin SK. Hepatic visceral larva migrans: evolution of the lesion, diagnosis, and role of high-dose albendazole therapy. Am J Gastroenterol 1994; 89:624.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/10\" class=\"nounderline abstract_t\">Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992; 86:418.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/11\" class=\"nounderline abstract_t\">Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987; 18:507.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/12\" class=\"nounderline abstract_t\">Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991; 104:27.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/13\" class=\"nounderline abstract_t\">Oostburg BF. The sixth case of lagochilascariasis minor in Surinam. Trop Geogr Med 1992; 44:154.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/14\" class=\"nounderline abstract_t\">Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994; 88:200.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/15\" class=\"nounderline abstract_t\">Krepel HP, Haring T, Baeta S, Polderman AM. Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole. Trans R Soc Trop Med Hyg 1993; 87:87.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/16\" class=\"nounderline abstract_t\">Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34:315.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/17\" class=\"nounderline abstract_t\">Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/18\" class=\"nounderline abstract_t\">Mill&aacute;n JC, Mull R, Freise S, et al. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63:264.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/19\" class=\"nounderline abstract_t\">Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33:1.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/20\" class=\"nounderline abstract_t\">Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998; 45:601.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/21\" class=\"nounderline abstract_t\">Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982; 76:114.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/22\" class=\"nounderline abstract_t\">Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002; 185:805.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/23\" class=\"nounderline abstract_t\">Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001; 358:1873.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/24\" class=\"nounderline abstract_t\">Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.</a></li><li><a href=\"https://www.uptodate.com/contents/anthelminthic-therapies/abstract/25\" class=\"nounderline abstract_t\">Zumaquero-R&iacute;os JL, Sarracent-P&eacute;rez J, Rojas-Garc&iacute;a R, et al. Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide. PLoS Negl Trop Dis 2013; 7:e2553.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 487 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21576510\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">IVERMECTIN</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">BENZIMIDAZOLES</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Albendazole</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Mebendazole</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Triclabendazole</a></li><li><a href=\"#H21576281\" id=\"outline-link-H21576281\">Thiabendazole</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">PRAZIQUANTEL</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">OTHER AGENTS</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">Diethylcarbamazine</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Pyrantel</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Nitazoxanide</a></li><li><a href=\"#H21576467\" id=\"outline-link-H21576467\">Oxamniquine</a></li></ul></li><li><a href=\"#H21576510\" id=\"outline-link-H21576510\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=ascariasis\" class=\"medical medical_review\">Ascariasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=enterobiasis-pinworm-and-trichuriasis-whipworm\" class=\"medical medical_review\">Enterobiasis (pinworm) and trichuriasis (whipworm)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">Giardiasis: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hookworm-infection\" class=\"medical medical_review\">Hookworm infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hookworm-related-cutaneous-larva-migrans\" class=\"medical medical_review\">Hookworm-related cutaneous larva migrans</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-flukes-fascioliasis\" class=\"medical medical_review\">Liver flukes: Fascioliasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=loiasis-loa-loa-infection\" class=\"medical medical_review\">Loiasis (Loa loa infection)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mass-drug-administration-for-control-of-parasitic-infections\" class=\"medical medical_review\">Mass drug administration for control of parasitic infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=miscellaneous-nematodes\" class=\"medical medical_review\">Miscellaneous nematodes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=onchocerciasis\" class=\"medical medical_review\">Onchocerciasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pediculosis-capitis\" class=\"medical medical_review\">Pediculosis capitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=scabies-epidemiology-clinical-features-and-diagnosis\" class=\"medical medical_review\">Scabies: Epidemiology, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=strongyloidiasis\" class=\"medical medical_review\">Strongyloidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-cryptosporidiosis\" class=\"medical medical_review\">Treatment and prevention of cryptosporidiosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis\" class=\"medical medical_review\">Treatment and prevention of schistosomiasis</a></li></ul></div></div>","javascript":null}